Your Solutions
BIOMEDTRACKER
Real-time Event Tracking & Drug Development Analysis
管線研發追蹤、獲批前景分析、商業資訊、調研報告
DATAMONITOR HEALTHCARE
Disease Competitive Analysis, 10-20 Years Market Forecast, KOL Insights
疾病競爭分析、10-20年市場預測、KOL專訪
Meet the team
Julie Guan (China)
Head of Strategic Accounts
Citeline
Youmin Zhu (China)
Client Success Manager
Citeline
Training & Help
We provide product training support via online sessions/pre-recorded materials, please click below to access relevant contents, or reach out to this email for any customized training request: [email protected]
我們提供各產品的使用培訓支持，請點擊下列查閲相關培訓資源，若有特定培訓需求或安排則可聯絡：[email protected]
For access or technical issues, please contact your dedicated support team via 'Meet the Team', or contact Client Service team via below email:
若有任何登錄問題，請切換至Meet the Team版面並聯絡對接服務團隊，或可聯絡全球/亞太客服團隊：
Global - [email protected] (English only)
APAC - [email protected] (via English/Chinese)
Require Research Support?
Ask-the-Analyst™
Ask-the-Analyst™
Your status as a loyalty partner includes unlimited access to our highly acclaimed Ask-the-Analyst™ service. With a 24-hour response time, Ask-the-Analyst offers you authoritative information to help you make faster, smarter business decisions.
作爲重點合作夥伴，貴司用戶均可無限量使用「Ask-the-Analyst™」分析師咨詢服務。分析師團隊將會在24小時内回復（工作日），并爲您提供信息收集或專業見解，最終助您做出更快、更明智的業務決策。
Our Ask-the-Analyst team of industry experts leverages the complete suite of pharma intelligence products and publicly available sources to bring you the answers you’re looking for, while your information and all questions received are strictly confidential.
由業界專家組成的Ask the Analyst團隊將結合内部數據與公開領域資源爲您提供相關信息支持，您的個人資訊與提問内容均會被嚴格保密。
Latest Pharma Monthly Newsletter
Edition: May 2026
EDITORIAL CONTENTS (incl. Podcasts, Webinars)
- Podcast: Drug Fix - Potential Nondisclosure Agreements For US FDA Staff, Hiring Threatens User Fee Reductions (Listen)
- Webinar: ASCO 2026 - Key Insights and Innovations (Watch Now)
- Webinar: World Preview 2026 (Watch Now)
- Webinar: China Pipelines, Western Portfolios (2pm GMT, July 14 | Register)
DEALS & FINANCING (incl. M&As, Licensing, Financing)
- M&A: CVC Capital Partners Launches €10.7B Offer to Buy Recordati
- M&A: Angelini Pharma to Acquire Catalyst Pharmaceuticals for $4.1B
- M&A: Bayer Enters Agreement To Acquire Perfuse Therapeutics For Up To $2.45B
- Licensing: Hengrui Pharma and Bristol Myers Squibb Enter Potential $15.2B Agreement to Advance 13 Programs Across Oncology, Hematology, and Immunology ($600M upfront)
- Licensing: Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines totalling $10.5B ($650M upfront)
- Licensing: Boston Scientific Invests $1.5B in MiRus; Gets Option to Acquire TAVR Business
- Financing: Hemab Therapeutics Nets $322M in IPO; Overallotment Exercised
- Financing: Odyssey Therapeutics Nets $259.5M in Revived IPO
- Financing: Isomorphic Labs Brings in $2B in Series B Round
KEY R&D EVENTS (incl. Top-line Readouts, Analyst Commentary, Approval/CRL)
- Positive: Revolution Medicines | Phase III RASolute 302 Trial Reveals Daraxonrasib's Unprecedented HR 0.40 OS Benefit in 2L mPDAC, Setting the Bar for the Pan-RAS Class
- Positive: Cogent Biosciences | PEAK delivers the first positive 2L GIST Phase 3 in 20 years, with mechanism-validated subgroups and a manageable hepatotoxicity signal
- Positive: Akeso | HARMONi-6 delivers a compelling OS benefit in squamous NSCLC, but Western generalizability remains unproven pending HARMONi-3
- Positive: BioMarin | Voxzogo Aces Phase 3 Skeletal Dysplasia Expansion, Potentially Doubling Addressable Market with Minimal Regulatory Risk
- Positive: Eli Lilly | Pivotal Phase III results for Lilly’s retatrutide demonstrate ground breaking weight loss potential in obesity
- Negative: Aardvark | FDA places full clinical hold on ARD-101 Phase 3 HERO program in Prader-Willi syndrome (PWS), triggering reassessment of development path
- Negative: Regeneron | fianlimab plus Libtayo falls behind expectations with a missed PFS mark in first-line unresectable melanoma
- Negative: Oculis | OCS-01 Phase III DIAMOND program fails to meet primary endpoint, ending regulatory path in diabetic macular edema (DME)
RESEARCH REPORTS (incl. Forecast, Thought Leadership, KOL Interview)
- Report: Annual Completed Clinical Trials Report 2026 (Link)
- Report: ASCO 2026 - Planner | Pre-ASCO | Weekend Update
- Report: Dealmaking / Financing Quarterly Statistics, Q1 2026
- Report: Q2 2026 Outlook Report
- Report: Inside the ADC Deal Surge
- Report: Diabetes Management: Blood Glucose Monitoring Devices
- Report: Epi & Market Forecast - Type-1 Diabetes | Dry Eye Disease | Multiple Sclerosis | Schizophrenia
- Report: KOL Interview - Chronic Myeloid Leukemia | Dry Eye Disease
Latest Editorial Podcasts
